Business
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with obstructive sleep apnea NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Auvelity® (dextromethorphan-bupropion), Sunosi® (solriamfetol), and disease state at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held from May 30-June 3 in Miami. The presentations on Auvelity incorporate new data and post-hoc analyses including demonstration of functional improvement in patients with major depressive disorder (MDD). The presentations on Sunosi include data from the SHARP (Solriamfetol’s Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled) study demonstrating improvement in cognitive function in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). “MDD is the leading cause of disability worldwide and improvement in functioning is critically important to people with MDD. Workplace costs, which are driven by presenteeism, are the major driver of the total economic burden of MDD, which exceeds $326 billion in the United States1,” said Andrew Cutler, MD, Associate Clinical Professor of Psychiatry, SUNY Upstate Medical University and Chief Medical Officer, Neuroscience Education Institute. “These data add to the existing clinical evidence for Auvelity in improving patient-centered outcomes in MDD and demonstrate the potential for Auvelity to improve functional impairment in MDD and to reduce key drivers of MDD-related costs.” Details for the upcoming ASCP presentations are as follows: Title: AXS-05 (Dextromethorphan-Bupropion) Significantly Improved Functioning in Major Depressive Disorder: Analysis of the Domains of the Sheehan Disability ScaleOral Session: Poinciana 1 2Lead Author: Andrew Cutler, MD, SUNY Upstate Medical University and Neuroscience Education InstituteDate/Time: Tuesday, May 30, 2023, from 4:15 p.m. – 4:30 p.m. ET Title: Impact of AXS-05 (Dextromethorphan-Bupropion) on Patient-Reported Insomnia Symptoms: Results...